Correct Answer: C. Intravenous digoxin
Intravenous digoxin is contraindicated in acute high-altitude illness (HAI) and has no role in its management. At 3000 m, the person is experiencing acute hypoxia leading to breathlessness, likely acute mountain sickness (AMS) or early high-altitude cerebral edema (HACE). Digoxin is a cardiac glycoside used for heart failure and arrhythmias—conditions not present in uncomplicated HAI. More critically, digoxin increases myocardial irritability in the hypoxic state, raising the risk of arrhythmias. The hypoxic pulmonary vasoconstriction and increased sympathetic tone at altitude already predispose to arrhythmias; digoxin would worsen this. Additionally, digoxin has a narrow therapeutic window and requires renal clearance; hypoxia impairs renal function, risking toxicity. The management of HAI focuses on reducing hypoxic stress: oxygen supplementation improves arterial oxygen saturation, acetazolamide (a carbonic anhydrase inhibitor) reduces fluid retention and improves ventilation by causing metabolic acidosis, and immediate descent is the definitive treatment. None of these address the underlying problem like digoxin does—in fact, digoxin adds iatrogenic risk without therapeutic benefit.
Why the other options are wrong
A. Acetazolamide — Acetazolamide is a first-line agent for AMS and HACE prevention/treatment. It inhibits carbonic anhydrase, causing metabolic acidosis that stimulates ventilation and reduces fluid retention in tissues. At 3000 m, it reduces the incidence of AMS by ~50% and is recommended by Indian high-altitude medicine guidelines. This is a standard DOC, not an exception. B. Immediate descent — Descent is the gold-standard, definitive treatment for any symptomatic HAI. Even a 500–1000 m descent significantly improves oxygenation and symptom relief. In Indian mountainous regions (Himalayas, Ladakh), immediate descent is always advised for symptomatic individuals. This is the most effective intervention, not an exception. D. Oxygen supplementation — Supplemental oxygen directly corrects the underlying hypoxemia causing breathlessness. It raises arterial PaO₂, reduces hypoxic pulmonary vasoconstriction, and provides symptomatic relief. Oxygen is a cornerstone of acute HAI management in Indian high-altitude medical protocols. This is essential, not an exception.
High-Yield Facts
- Acetazolamide 250 mg BD is the standard prophylaxis and treatment for AMS; it works by inducing metabolic acidosis and reducing fluid retention.
- Immediate descent by ≥500 m is the definitive treatment for any symptomatic high-altitude illness and should not be delayed.
- Digoxin is contraindicated in acute hypoxia because it increases myocardial irritability and arrhythmia risk in the already-sensitized hypoxic heart.
- Oxygen supplementation is the first-line acute symptomatic relief for breathlessness at altitude, raising SaO₂ and reducing hypoxic stress.
- HACE (High-Altitude Cerebral Edema) presents with ataxia, confusion, and altered consciousness; it requires immediate descent and dexamethasone, not digoxin.
Mnemonics
HAI Management: AOD Acetazolamide (prophylaxis/treatment), Oxygen (acute relief), Descent (definitive). Remember: Digoxin is not part of this trio. Why NOT Digoxin at Altitude Digoxin = Dangerous in hypoxia (arrhythmia risk). Think: Hypoxia + Digoxin = Dysrhythmia. Avoid it.
NBE Trap
NBE pairs "high altitude" with "breathlessness" to lure students into thinking of cardiac causes (heart failure, pulmonary edema) where digoxin might seem relevant. However, uncomplicated HAI is a respiratory/hypoxic problem, not a cardiac one—digoxin adds harm without benefit and is explicitly contraindicated.
Clinical Pearl
In Indian trekking regions (Himalayas, Ladakh), trekkers presenting with breathlessness at 3000+ m should be given oxygen and acetazolamide, then descended—not given digoxin. A climber with AMS who receives digoxin risks life-threatening arrhythmias in the hypoxic state, a preventable iatrogenic disaster.
_Reference: Harrison Ch. 298 (High-Altitude Medicine); KD Tripathi Ch. 15 (Respiratory Physiology); Guyton Ch. 42 (Hypoxia and Altitude)_